Pemigatinib for Cholangiocarcinoma: An Interview With Ghassan Abou-Alfa, MD, MBA

Fibroblast growth factor receptor (FGFR) 2 gene alterations can occur in the pathogenesis of cholangiocarcinoma. Pemigatinib (PemazyreTM, Incyte Corporation), a newly FDA approved oral inhibitor of FGFR2, has shown efficacy in patients with previously treated, locally advanced, or metastatic cholangiocarcinoma with and without FGFR2 gene alterations. Approval was granted based a study led by Ghassan Abou-Alfa, MD, MBA from Memorial Sloan Kettering Cancer Center. In an interview with i3 Health, D...
Continue reading

Durvalumab for Extensive-Stage Small-Cell Lung Cancer: Jonathan Goldman, MD

In this interview, Jonathan Goldman, MD, speaks with i3 Health about the recent FDA approval of durvalumab (Imfinzi®, AstraZeneca) in combination with platinum/etoposide for patients with extensive-stage small-cell lung cancer (ES-SCLC). The approval was based on CASPIAN, a phase 3 trial in which durvalumab/platinum/etoposide significantly increased median overall survival and produced a higher overall response rate compared with platinum/etoposide alone. Dr. Goldman, Associate Professor of Hema...
Continue reading

PSMA PET-CT For Staging High-Risk Prostate Cancer: An Interview With Michael Hofman, MBBS

Results from a multicenter, randomized study (ANZCTR12617000005358) have shown that prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) has superior efficacy in staging men with high-risk localized prostate cancer compared with conventional imaging using computed tomography (CT) and bone scan. In an interview with i3 Health, lead investigator from the study, Michael Hofman, MBBS, discusses challenges of treating patients with high-risk prostate can...
Continue reading

Managing Breast Cancer Treatment During COVID-19: Jill Dietz, MD, FACS

How should cancer care providers balance the needs of treatment against the risk of COVID-19? A group of representatives from multiple cancer care organizations with expertise in the multidisciplinary management of breast cancer has sought to answer this question through their set of recommendations for prioritizing, treating, and triaging patients with breast cancer during the pandemic. In this interview with i3 Health, Jill R. Dietz, MD, FACS, President of the American Society of Breast Surgeo...
Continue reading

Digital Breast Tomosynthesis for Breast Cancer Screening: Diana Miglioretti, PhD

In women undergoing screening for breast cancer, high recall rates—the proportion of patients who need to have their screening examination repeated due to a false-positive initial assessment—are often associated with increased costs and heightened patient anxiety. While the American College of Radiology recommends an upper threshold of 12% for recall rate, only 62.2% of radiologists meet this recommendation. In a recent study, Diana Miglioretti, PhD, Division Chief of Biostatistics at the U...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.